UNSPSC 51372303: Prodine

This classification denotes an opioid and analgesic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21J54X4Z4Z, chemically known as 1,3-dimethyl-4-phenyl-4-propionoxypiperidine but generally known as betaprodine, which bears US NIH Compound Identifier 6471. European Medicines Agency schedules Betaprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05802MIG. The term BETAPRODINE is an International Non-Proprietary Name.

BETAPRODINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1(C(CN(CC1)C)C)C1CCCCC1)C(=O)CC.

UNSPSC 51372303 Prodine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, over-the-counter medicines, generic multi-source pharmaceuticals, and drug deactivation systems for public health and community health initiatives. Recent solicitations show state health agencies and county health departments acquiring these products through competitive bidding to support emergency response, pharmacy benefit programs, and community health services. The work involves sourcing products that meet FDA compliance standards, maintaining specific shelf-life and expiration requirements, and coordinating delivery to public health facilities. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of multiple member jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors typically must demonstrate cGMP and Drug Supply Chain Security Act compliance, maintain specified insurance coverage including commercial general liability of $2 million to $5 million, and accept administrative fees ranging from 3 percent upward.